Acute Repetitive Seizures Market To Reach $6.48 Billion By 2030

Acute Repetitive Seizures Market Growth & Trends

The global acute repetitive seizures market size is estimated to reach USD 6.48 billion by 2030, expanding at a CAGR of 12.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of initiatives to increase awareness about epilepsy is the major factor driving the market.

The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with a few major companies and a high market share.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.

There are several routes of drug administration; out of which, the nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.

 Request a free sample copy or view report summary: Acute Repetitive Seizures Market Report

Acute Repetitive Seizures Market Report Highlights

• Global acute repetitive seizures market size was estimated at USD 3.15 billion in 2024 and is expected to register a CAGR of 12.7% over the forecast period

• USL-261 dominated the market and accounted for a share of 44.5% in 2024, owing to its effectiveness as an intranasal treatment aimed at achieving rapid seizure control.

• North America acute repetitive seizures market dominated the global market with a revenue share of 43.0% in 2024. Market growth in the region is driven by a high prevalence of epilepsy and neurological disorders, complemented by a robust healthcare infrastructure.

• The acute repetitive seizures market in Japan dominated the Asia Pacific acute repetitive seizures market in 2024. The aging population, coupled with rising awareness of neurological disorders, stimulates demand for effective therapies.

Acute Repetitive Seizures Market Segmentation

Grand View Research has segmented the global acute repetitive seizures market based on product and region:

Acute Repetitive Seizures Product Outlook (Revenue, USD Million, 2018 - 2030)

• USL-261

• NRL-1

• AZ-002

• Diastat Rectal Gel

• Others

Acute Repetitive Seizures Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List Of Key Players in the Acute Repetitive Seizures Market

• UCB S.A. Belgium

• Neurelis, Inc.

• Bausch Health Companies Inc.

• Grupo Ferrer Internacional, S.A.

• SERB